IFT88: A Potential Drug Target and Biomarker for PKD (G8100)

Target Name: IFT88

NCBI ID: G8100

IFT88

IFT88: A Potential Drug Target and Biomarker for PKD

Recessive polycystic kidney disease (PKD) is a genetic disorder that affects the development and function of the kidney, leading to the development of cysts in the kidneys. It is a progressive disease that can cause significant kidney function loss and a decline in a person's quality of life. Currently, there are no cure for PKD, and treatment is limited to managing symptoms and preventing complications. Therefore, identifying potential drug targets and biomarkers for this disease is of great interest.

In this article, we will focus on IFT88, a protein that is expressed in the kidney and has been identified as a potential drug target for PKD. We will explore the structure and function of IFT88 and discuss its potential as a drug target and as a biomarker for PKD.

Structure and Function of IFT88

IFT88 is a 737- amino acid protein that is expressed in the kidney, specifically in the podocytes, which are a type of kidney cell that forms the glomeruli, the filtering units of the kidney. IFT88 is a member of the superfamily of cytoplasmic proteins, which are involved in various cellular processes in the body, including the regulation of ion and water transport, as well as the maintenance of cell structure and integrity.

IFT88 is a monocystic protein, which means that it is composed of a single polypeptide chain that is secreted from the cell and is maintained in the extracellular space. It has a molecular weight of 11.9 kDa and a pre-fusion cleavage site at its N-terminus.

Expression and localization of IFT88

IFT88 is expressed in the kidney, where it is mainly found in the podocytes, which are the glomerular filtration units (GFUs) of the kidney. The podocytes are responsible for maintaining the structure and integrity of the glomerulus, and IFT88 is thought to be involved in this process. IFT88 is also expressed in other tissues, including the liver, heart, and skeletal muscle.

IFT88 is predominantly localized to the podocytes in the kidney, and it is present in the cytoplasm of these cells. It is also co-expressed with other proteins, including the transcription factor p21, which is known to play a role in the regulation of IFT88 expression.

Potential Drug Target for PKD

IFT88 has been identified as a potential drug target for PKD due to its unique structure and function. It is a protein that is expressed in the kidney, which is the site of the disease, and it is involved in the maintenance of the structure and integrity of the kidney cells. Therefore, drugs that can target IFT88 may have a unique mechanism of action and may be effective in treating PKD.

One potential mechanism of action for IFT88-based treatments is the inhibition of its expression. This can be achieved through various means, such as downregulating the gene expression, or through inhibition of the protein itself. By inhibiting IFT88 expression, it is possible to reduce the number of cysts that develop in the kidneys, leading to improved kidney function and reduced symptoms of PKD.

Another potential mechanism of action for IFT88-based treatments is the stimulation of its degradation. This can be achieved through various means, such as increasing the levels of a protein called ubiquitin, which can bind to and degradation IFT88. By increasing the degradation of IFT88, it is possible to reduce its levels in the kidneys, which may lead to the regression of cysts.

IFT88 as a Biomarker for PKD

IFT88 has also been identified as a potential biomarker for PKD. The development of cysts in the kidney is a key feature of PKD, and IFT88 has

Protein Name: Intraflagellar Transport 88

Functions: Positively regulates primary cilium biogenesis (PubMed:17604723). Also involved in autophagy since it is required for trafficking of ATG16L and the expansion of the autophagic compartment

The "IFT88 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFT88 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets